{"pii": "S016882782102105X", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "attachments", "$$": [{"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S016882782102105X-ga1.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S016882782102105X/ga1/DOWNSAMPLED/image/jpeg/b943d2b1d4abdc5c46a65f81940cc7b1/ga1.jpg"}, {"#name": "file-basename", "_": "ga1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "ga1.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "27768"}, {"#name": "pixel-height", "_": "200"}, {"#name": "pixel-width", "_": "474"}, {"#name": "attachment-type", "_": "IMAGE-DOWNSAMPLED"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S016882782102105X-ga1.sml"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S016882782102105X/ga1/THUMBNAIL/image/gif/4a08a3cafa3a848bfd7ede92a7fb75c6/ga1.sml"}, {"#name": "file-basename", "_": "ga1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "ga1.sml"}, {"#name": "extension", "_": "sml"}, {"#name": "filesize", "_": "8062"}, {"#name": "pixel-height", "_": "92"}, {"#name": "pixel-width", "_": "219"}, {"#name": "attachment-type", "_": "IMAGE-THUMBNAIL"}]}, {"#name": "attachment", "$": {"xmlns:xocs": true}, "$$": [{"#name": "attachment-eid", "_": "1-s2.0-S016882782102105X-ga1_lrg.jpg"}, {"#name": "ucs-locator", "_": "https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S016882782102105X/ga1/HIGHRES/image/jpeg/8678a6116110abcd00f73ee38b0fec99/ga1_lrg.jpg"}, {"#name": "file-basename", "_": "ga1"}, {"#name": "abstract-attachment", "_": "true"}, {"#name": "filename", "_": "ga1_lrg.jpg"}, {"#name": "extension", "_": "jpg"}, {"#name": "filesize", "_": "201044"}, {"#name": "pixel-height", "_": "886"}, {"#name": "pixel-width", "_": "2099"}, {"#name": "attachment-type", "_": "IMAGE-HIGH-RES"}]}]}, {"#name": "abstract", "$": {"lang": "en", "id": "abs0010", "view": "all", "class": "author"}, "$$": [{"#name": "abstract-sec", "$": {"role": "background", "id": "abssec0010", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0010"}, "_": "Background & Aims"}, {"#name": "simple-para", "$": {"id": "abspara0010", "view": "all"}, "_": "Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. The advanced stage of NAFLD, non-alcoholic steatohepatitis (NASH), has been recognized as a leading cause of end-stage liver injury for which there are no FDA-approved therapeutic options. Glutathione S-transferase Mu 2 (GSTM2) is a phase II detoxification enzyme. However, the roles of GSTM2 in NASH have not been elucidated."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0015"}, "_": "Methods"}, {"#name": "simple-para", "$": {"id": "abspara0015", "view": "all"}, "$$": [{"#name": "__text__", "_": "Multiple RNA-seq analyses were used to identify hepatic GSTM2 expression in NASH. "}, {"#name": "italic", "_": "In\u00a0vitro"}, {"#name": "__text__", "_": " and "}, {"#name": "italic", "_": "in\u00a0vivo"}, {"#name": "__text__", "_": " gain- or loss-of-function approaches were used to investigate the role and molecular mechanism of GSTM2 in NASH."}]}]}, {"#name": "abstract-sec", "$": {"role": "results", "id": "abssec0020", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0020"}, "_": "Results"}, {"#name": "simple-para", "$": {"id": "abspara0020", "view": "all"}, "_": "We identified GSTM2 as a sensitive responder and effective suppressor of NASH progression. GSTM2 was significantly downregulated during NASH progression. Hepatocyte GSTM2 deficiency markedly aggravated insulin resistance, hepatic steatosis, inflammation and fibrosis induced by a high-fat diet and a high-fat/high-cholesterol diet. Mechanistically, GSTM2 sustained MAPK pathway signaling by directly interacting with apoptosis signal-regulating kinase 1 (ASK1). GSTM2 directly bound to the N-terminal region of ASK1 and inhibited ASK1 N-terminal dimerization to subsequently repress ASK1 phosphorylation and the activation of its downstream JNK/p38 signaling pathway under conditions of metabolic dysfunction."}]}, {"#name": "abstract-sec", "$": {"role": "conclusion", "id": "abssec0025", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0025"}, "_": "Conclusions"}, {"#name": "simple-para", "$": {"id": "abspara0025", "view": "all"}, "_": "These data demonstrated that hepatocyte GSTM2 is an endogenous suppressor that protects against NASH progression by blocking ASK1 N-terminal dimerization and phosphorylation. Activating GSTM2 holds promise as a therapeutic strategy for NASH."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0030", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0030"}, "_": "Clinical trial number"}, {"#name": "simple-para", "$": {"id": "abspara0030", "view": "all"}, "_": "IIT-2021-277."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0035", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0035"}, "_": "Lay summary"}, {"#name": "simple-para", "$": {"id": "abspara0035", "view": "all"}, "_": "New therapeutic strategies for non-alcoholic steatohepatitis are urgently needed. We identified that the protein GSTM2 exerts a protective effect in response to metabolic stress. Therapies that aim to increase the activity of GSTM2 could hold promise for the treatment of non-alcoholic steatohepatitis."}]}]}, {"#name": "abstract", "$": {"class": "graphical", "id": "abs0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0040"}, "_": "Graphical abstract"}, {"#name": "abstract-sec", "$": {"id": "abssec0040", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0040", "view": "all"}, "$$": [{"#name": "display", "$$": [{"#name": "figure", "$": {"id": "undfig1"}, "$$": [{"#name": "link", "$": {"xmlns:xlink": true, "locator": "ga1", "type": "simple", "role": "http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4", "href": "pii:S016882782102105X/ga1", "id": "aep-link-id10"}}]}]}]}]}]}, {"#name": "abstract", "$": {"class": "author-highlights", "lang": "en", "id": "abs0020", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0045"}, "_": "Highlights"}, {"#name": "abstract-sec", "$": {"id": "abssec0045", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0045", "view": "all"}, "$$": [{"#name": "list", "$": {"id": "ulist0010"}, "$$": [{"#name": "list-item", "$": {"id": "u0010"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0010", "view": "all"}, "_": "GSTM2 is downregulated in patients and mice with NASH."}]}, {"#name": "list-item", "$": {"id": "u0015"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0015", "view": "all"}, "_": "Deficiency of GSTM2 promotes steatosis, inflammation and fibrosis in preclinical models of NASH."}]}, {"#name": "list-item", "$": {"id": "u0020"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0020", "view": "all"}, "_": "Deficiency of GSTM2 augments NASH by promoting ASK1 dimerization and activation in hepatocytes."}]}, {"#name": "list-item", "$": {"id": "u0025"}, "$$": [{"#name": "label", "_": "\u2022"}, {"#name": "para", "$": {"id": "p0025", "view": "all"}, "_": "Targeting GSTM2 might be a valuable therapeutic approach in NASH."}]}]}]}]}]}]}}